FindTrial
Sign In

Study on the individualized administration of meropenem in children critical infection

Study on the individualized administration of meropenem in children critical infection

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056880
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-05-01
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal infection

Interventions

Experimental group:Carbapenems were infused intravenously

Sponsors

Zhongda Hospital, Southeast University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 12 Years

Inclusion criteria

Inclusion criteria: 1. Aged 0-12 years; 2. No gender limit; 3. Empiric or targeted use of meropenem as anti-infective therapy; 4. Meropenem treatment for more than 3 days; 5. Patients with complete clinical evaluation data.

Exclusion criteria

Exclusion criteria: 1. Allergic to meropenem and related excipients; 2. The blood concentration of carbapenem antibiotics was not monitored during treatment; 3. Those who are not considered by the investigator to be eligible for the study.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy rate;—

Secondary

MeasureTime frame
Microbial eradication rate;—

Countries

China

Contacts

Public ContactHe Jie
13011014975@163.com+86 25 83272127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026